Woodline Partners LP Sells 249,428 Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR)

Woodline Partners LP lessened its stake in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) by 50.4% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 245,676 shares of the company's stock after selling 249,428 shares during the period. Woodline Partners LP owned about 1.64% of Jasper Therapeutics worth $5,253,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the stock. Wells Fargo & Company MN raised its stake in shares of Jasper Therapeutics by 106.7% during the 4th quarter. Wells Fargo & Company MN now owns 7,415 shares of the company's stock worth $159,000 after purchasing an additional 3,828 shares in the last quarter. EntryPoint Capital LLC acquired a new position in Jasper Therapeutics during the fourth quarter worth $223,000. Tema Etfs LLC bought a new stake in Jasper Therapeutics during the fourth quarter worth $266,000. JPMorgan Chase & Co. lifted its stake in Jasper Therapeutics by 239.8% in the third quarter. JPMorgan Chase & Co. now owns 16,391 shares of the company's stock valued at $308,000 after acquiring an additional 11,567 shares during the last quarter. Finally, Rhumbline Advisers grew its position in shares of Jasper Therapeutics by 12.6% in the 4th quarter. Rhumbline Advisers now owns 14,761 shares of the company's stock valued at $316,000 after acquiring an additional 1,652 shares during the period. 79.85% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on JSPR shares. UBS Group cut their target price on shares of Jasper Therapeutics from $38.00 to $33.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. Oppenheimer cut their price objective on Jasper Therapeutics from $80.00 to $65.00 and set an "outperform" rating for the company in a research report on Thursday, May 15th. Finally, HC Wainwright reissued a "buy" rating and set a $40.00 target price on shares of Jasper Therapeutics in a report on Tuesday, March 11th. Ten equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $62.22.

Jasper Therapeutics Price Performance

Shares of NASDAQ JSPR remained flat at $4.77 during trading hours on Tuesday. The stock had a trading volume of 132,289 shares, compared to its average volume of 292,576. The company has a market cap of $71.65 million, a price-to-earnings ratio of -1.01 and a beta of 2.74. The company's 50 day simple moving average is $4.54 and its two-hundred day simple moving average is $10.10. Jasper Therapeutics, Inc. has a one year low of $3.13 and a one year high of $26.84.

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported ($1.41) EPS for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.24). On average, research analysts predict that Jasper Therapeutics, Inc. will post -4.47 EPS for the current fiscal year.

Jasper Therapeutics Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.